Comparing RedHill Biopharma (NASDAQ:RDHL) and Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Institutional and Insider Ownership

99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are held by institutional investors. 2.9% of Astria Therapeutics shares are held by company insiders. Comparatively, 6.8% of RedHill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Astria Therapeutics and RedHill Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astria Therapeutics	0	0	5	1	3.17
RedHill Biopharma	0	0	0	0	0.00

Astria Therapeutics currently has a consensus target price of $25.60, suggesting a potential upside of 243.62%. Given Astria Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Astria Therapeutics is more favorable than RedHill Biopharma.

Volatility & Risk

Astria Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.69, suggesting that its stock price is 269% more volatile than the S&P 500.

Earnings & Valuation

This table compares Astria Therapeutics and RedHill Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astria Therapeutics	N/A	N/A	-$72.89 million	($2.09)	-3.56
RedHill Biopharma	$3.71 million	2.02	$23.92 million	($10.00)	-0.59

RedHill Biopharma has higher revenue and earnings than Astria Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than RedHill Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Astria Therapeutics and RedHill Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Astria Therapeutics	N/A	-43.58%	-29.36%
RedHill Biopharma	N/A	N/A	N/A

Summary

RedHill Biopharma beats Astria Therapeutics on 7 of the 13 factors compared between the two stocks.

About Astria Therapeutics

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.